URGN
UroGen Pharma Ltd.
Price Chart
Latest Quote
$32.81
+0.86 (+2.69%)
Current Price
| Previous Close | $31.95 |
| Open | $32.50 |
| Day High | $33.40 |
| Day Low | $32.17 |
| Volume | 533,688 |
Stock Information
| Shares Outstanding | 48.72M |
| Total Debt | $197.09M |
| Cash Equivalents | $140.27M |
| Revenue | $140.49M |
| Net Income | $-133.22M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.60B |
| EPS (TTM) | $-2.74 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.61B |
| Sales | $140.49M |
| Income | $-133.22M |
| Book/sh | $-2.55 |
| Cash/sh | $2.88 |
| Employees | 298 |
Financial Ratios
| Quick Ratio | 3.87 |
| Current Ratio | 4.69 |
Returns & Margins
| ROA | -26.98% |
| Gross Margin | 89.85% |
| Operating Margin | -39.76% |
| Profit Margin | -94.83% |
Ownership
| Insider Ownership | 3.65% |
| Institutional Ownership | 100.59% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 26.70 |
| P/S | 11.38 |
| P/B | -12.86 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $36.88 |
Technical Indicators
| SMA20 | $28.87 |
| SMA50 | $26.50 |
| SMA200 | $22.03 |
| RSI | 70.04 |
| ATR | 1.6754 |
| Shares Float | 43.17M |
| Short Float | 14.49% |
| Short Ratio | 7.76 |
| Volatility | 1.62 |
| Rel Volume | 0.83 |
Performance History
| Week | +17.18% |
| Month | +14.80% |
| Quarter | +77.54% |
| 6 Months | +43.59% |
| YTD | +44.47% |
| Year | +128.80% |
| 3 Years | +173.19% |
| 5 Years | +89.22% |
| 10 Years | +134.69% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $32.81 | 533,688 |
| 2026-06-16 | $31.95 | 572,000 |
| 2026-06-15 | $30.86 | 804,900 |
| 2026-06-12 | $29.72 | 585,000 |
| 2026-06-11 | $29.50 | 528,600 |
| 2026-06-10 | $28.00 | 618,800 |
| 2026-06-09 | $28.18 | 830,900 |
| 2026-06-08 | $27.25 | 671,600 |
| 2026-06-05 | $26.85 | 704,100 |
| 2026-06-04 | $27.60 | 329,800 |
| 2026-06-03 | $26.60 | 489,100 |
| 2026-06-02 | $26.54 | 758,500 |
| 2026-06-01 | $27.03 | 1,068,000 |
| 2026-05-29 | $28.13 | 878,200 |
| 2026-05-28 | $28.69 | 374,300 |
| 2026-05-27 | $29.33 | 496,900 |
| 2026-05-26 | $29.46 | 611,200 |
| 2026-05-22 | $28.89 | 364,400 |
| 2026-05-21 | $29.88 | 789,700 |
| 2026-05-20 | $30.22 | 789,300 |
| 2026-05-19 | $28.26 | 555,500 |
| 2026-05-18 | $28.58 | 830,700 |
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft fÃŧr klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
đ° Latest News
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Motley Fool âĸ 2026-06-14T15:34:38Z
Will UroGenâs Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative?
Simply Wall St. âĸ 2026-06-08T10:06:16Z
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
Motley Fool âĸ 2026-05-23T22:40:03Z
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Motley Fool âĸ 2026-05-23T22:33:51Z
How UGN-103âs Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors
Simply Wall St. âĸ 2026-05-21T21:18:10Z
Sector Update: Healthcare Stocks Gain Late Afternoon
MT Newswires âĸ 2026-05-19T19:55:35ZUroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says
MT Newswires âĸ 2026-05-19T14:55:25ZUrogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
Zacks âĸ 2026-05-11T13:55:02Z
Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch Momentum
Simply Wall St. âĸ 2026-05-09T03:18:54Z
UroGen (URGN) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-07T16:26:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $12,447,000 | $8,881,000 | $9,361,000 | $7,654,000 |
| Cost Of Revenue | $12,447,000 | $8,881,000 | $9,361,000 | $7,654,000 |
| Total Revenue | $109,788,000 | $90,398,000 | $82,713,000 | $64,357,000 |
| Operating Revenue | $109,788,000 | $90,398,000 | $82,713,000 | $64,357,000 |
| Expenses | ||||
| Interest Expense | $15,345,000 | $12,521,000 | $14,715,000 | $8,438,000 |
| Total Expenses | $234,651,000 | $187,180,000 | $148,249,000 | $143,398,000 |
| Other Income Expense | $-670,000 | $-229,000 | $838,000 | $72,000 |
| Other Non Operating Income Expenses | $-670,000 | $-229,000 | $838,000 | $72,000 |
| Net Non Operating Interest Income Expense | $-27,883,000 | $-27,031,000 | $-33,626,000 | $-29,059,000 |
| Total Other Finance Cost | $18,503,000 | $23,411,000 | $21,552,000 | $21,559,000 |
| Interest Expense Non Operating | $15,345,000 | $12,521,000 | $14,715,000 | $8,438,000 |
| Operating Expense | $222,204,000 | $178,299,000 | $138,888,000 | $135,744,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Net Interest Income | $-27,883,000 | $-27,031,000 | $-33,626,000 | $-29,059,000 |
| Interest Income | $5,965,000 | $8,901,000 | $2,641,000 | $938,000 |
| Normalized Income | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Net Income From Continuing And Discontinued Operation | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Total Operating Income As Reported | $-124,863,000 | $-96,782,000 | $-65,536,000 | $-79,041,000 |
| Net Income Common Stockholders | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Net Income | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Net Income Including Noncontrolling Interests | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Net Income Continuous Operations | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Pretax Income | $-153,416,000 | $-124,042,000 | $-98,324,000 | $-108,028,000 |
| Interest Income Non Operating | $5,965,000 | $8,901,000 | $2,641,000 | $938,000 |
| Operating Income | $-124,863,000 | $-96,782,000 | $-65,536,000 | $-79,041,000 |
| Gross Profit | $97,341,000 | $81,517,000 | $73,352,000 | $56,703,000 |
| Per Share | ||||
| Diluted EPS | $-3.19 | $-2.96 | $-3.55 | $-4.79 |
| Basic EPS | $-3.19 | $-2.96 | $-3.55 | $-4.79 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-135,660,000 | $-110,335,000 | $-81,904,000 | $-97,773,000 |
| Reconciled Depreciation | $2,411,000 | $1,186,000 | $1,705,000 | $1,817,000 |
| EBITDA (Bullshit earnings) | $-135,660,000 | $-110,335,000 | $-81,904,000 | $-97,773,000 |
| EBIT | $-138,071,000 | $-111,521,000 | $-83,609,000 | $-99,590,000 |
| Diluted Average Shares | $48,116,098 | $42,876,737 | $28,834,303 | $22,806,812 |
| Basic Average Shares | $48,116,098 | $42,876,737 | $28,834,303 | $22,806,812 |
| Diluted NI Availto Com Stockholders | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
| Tax Provision | $78,000 | $2,832,000 | $3,920,000 | $1,755,000 |
| Research And Development | $67,107,000 | $57,145,000 | $45,614,000 | $52,906,000 |
| Selling General And Administration | $155,097,000 | $121,154,000 | $93,274,000 | $82,838,000 |
| Total Unusual Items | - | $-23,411,000 | $-21,552,000 | $-21,559,000 |
| Total Unusual Items Excluding Goodwill | - | $-23,411,000 | $-21,552,000 | $-21,559,000 |
| Gain On Sale Of Security | - | $-23,411,000 | $-21,552,000 | $-21,559,000 |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-105,474,000 | $-8,803,000 | $-65,212,000 | $-89,361,000 |
| Total Assets | $200,455,000 | $285,711,000 | $178,311,000 | $135,619,000 |
| Total Non Current Assets | $14,431,000 | $9,576,000 | $9,125,000 | $6,712,000 |
| Other Non Current Assets | $5,338,000 | $765,000 | $2,263,000 | $2,963,000 |
| Investmentin Financial Assets | $0 | $5,022,000 | $4,502,000 | $0 |
| Current Assets | $186,024,000 | $276,135,000 | $169,186,000 | $128,907,000 |
| Other Current Assets | $14,672,000 | $8,845,000 | $10,281,000 | $11,101,000 |
| Restricted Cash | $1,350,000 | $1,076,000 | $821,000 | $813,000 |
| Inventory | $16,464,000 | $9,227,000 | $5,673,000 | $4,325,000 |
| Receivables | $33,082,000 | $20,302,000 | $15,443,000 | $12,704,000 |
| Accounts Receivable | $33,082,000 | $20,302,000 | $15,443,000 | $12,704,000 |
| Cash Cash Equivalents And Short Term Investments | $120,456,000 | $236,685,000 | $136,968,000 | $99,964,000 |
| Cash And Cash Equivalents | $110,745,000 | $171,987,000 | $95,002,000 | $55,408,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $11,465,000 | - | $3,549,000 | $42,129,000 |
| Total Debt | $128,332,000 | $123,387,000 | $99,395,000 | $99,123,000 |
| Long Term Debt And Capital Lease Obligation | $128,332,000 | $123,387,000 | $99,395,000 | $99,123,000 |
| Long Term Debt | $122,210,000 | $121,734,000 | $98,551,000 | $97,537,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $305,929,000 | $294,514,000 | $243,523,000 | $224,980,000 |
| Total Non Current Liabilities Net Minority Interest | $259,511,000 | $248,565,000 | $212,311,000 | $201,064,000 |
| Derivative Product Liabilities | $127,276,000 | $121,387,000 | $109,722,000 | $98,923,000 |
| Tradeand Other Payables Non Current | $3,903,000 | $3,791,000 | $3,194,000 | $3,018,000 |
| Current Liabilities | $46,418,000 | $45,949,000 | $31,212,000 | $23,916,000 |
| Other Current Liabilities | $5,185,000 | $7,948,000 | $3,860,000 | $3,276,000 |
| Payables And Accrued Expenses | $27,717,000 | $27,431,000 | $16,538,000 | $12,383,000 |
| Payables | $12,137,000 | $10,931,000 | $6,514,000 | $5,527,000 |
| Accounts Payable | $12,137,000 | $10,931,000 | $6,514,000 | $5,527,000 |
| Other Non Current Liabilities | - | - | - | $98,923,000 |
| Non Current Deferred Liabilities | - | - | - | $3,018,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | $3,018,000 |
| Equity | ||||
| Common Stock Equity | $-105,474,000 | $-8,803,000 | $-65,212,000 | $-89,361,000 |
| Total Equity Gross Minority Interest | $-105,474,000 | $-8,803,000 | $-65,212,000 | $-89,361,000 |
| Stockholders Equity | $-105,474,000 | $-8,803,000 | $-65,212,000 | $-89,361,000 |
| Gains Losses Not Affecting Retained Earnings | $19,000 | $56,000 | $12,000 | $-107,000 |
| Other Equity Adjustments | $19,000 | $56,000 | $12,000 | $-107,000 |
| Retained Earnings | $-959,716,000 | $-806,222,000 | $-679,348,000 | $-577,104,000 |
| Other | ||||
| Ordinary Shares Number | $48,350,272 | $42,231,746 | $32,490,119 | $23,129,953 |
| Share Issued | $48,350,272 | $42,231,746 | $32,490,119 | $23,129,953 |
| Tangible Book Value | $-105,474,000 | $-8,803,000 | $-65,212,000 | $-89,361,000 |
| Invested Capital | $16,736,000 | $112,931,000 | $33,339,000 | $8,176,000 |
| Working Capital | $139,606,000 | $230,186,000 | $137,974,000 | $104,991,000 |
| Capital Lease Obligations | $6,122,000 | $1,653,000 | $844,000 | $1,586,000 |
| Total Capitalization | $16,736,000 | $112,931,000 | $33,339,000 | $8,176,000 |
| Additional Paid In Capital | $854,090,000 | $797,248,000 | $614,035,000 | $487,787,000 |
| Capital Stock | $133,000 | $115,000 | $89,000 | $63,000 |
| Common Stock | $133,000 | $115,000 | $89,000 | $63,000 |
| Long Term Capital Lease Obligation | $6,122,000 | $1,653,000 | $844,000 | $1,586,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,516,000 | $10,570,000 | $10,814,000 | $8,257,000 |
| Current Accrued Expenses | $15,580,000 | $16,500,000 | $10,024,000 | $6,856,000 |
| Investments And Advances | $0 | $5,022,000 | $4,502,000 | $0 |
| Net PPE | $9,093,000 | $3,789,000 | $2,360,000 | $3,749,000 |
| Accumulated Depreciation | $-4,587,000 | $-4,281,000 | $-3,952,000 | $-3,150,000 |
| Gross PPE | $13,680,000 | $8,070,000 | $6,312,000 | $6,899,000 |
| Leases | $626,000 | $626,000 | $617,000 | $617,000 |
| Other Properties | $9,643,000 | $4,290,000 | $2,790,000 | $3,512,000 |
| Machinery Furniture Equipment | $3,411,000 | $3,154,000 | $2,905,000 | $2,770,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $5,422,000 | $4,522,000 | $2,877,000 | $2,019,000 |
| Raw Materials | $11,042,000 | $4,724,000 | $2,764,000 | $2,276,000 |
| Other Short Term Investments | $9,711,000 | $64,698,000 | $41,966,000 | $44,556,000 |
| Available For Sale Securities | - | $5,022,000 | $4,502,000 | - |
| Other Inventories | - | $-19,000 | $32,000 | $30,000 |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-162,733,000 | $-97,061,000 | $-76,570,000 | $-87,813,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-162,444,000 | $-96,766,000 | $-76,376,000 | $-87,559,000 |
| Cash Flow From Continuing Operating Activities | $-162,444,000 | $-96,766,000 | $-76,376,000 | $-87,559,000 |
| Operating Gains Losses | $2,865,000 | $15,077,000 | $11,504,000 | $14,007,000 |
| Investing Activities | ||||
| Capital Expenditure | $-289,000 | $-295,000 | $-194,000 | $-254,000 |
| Investing Cash Flow | $61,558,000 | $-20,613,000 | $-953,000 | $1,060,000 |
| Cash Flow From Continuing Investing Activities | $61,558,000 | $-20,613,000 | $-953,000 | $1,060,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $39,801,000 | $151,169,000 | $67,358,000 | $0 |
| Financing Cash Flow | $39,918,000 | $194,619,000 | $116,931,000 | $97,134,000 |
| Cash Flow From Continuing Financing Activities | $39,918,000 | $194,619,000 | $116,931,000 | $97,134,000 |
| Net Common Stock Issuance | $39,801,000 | $151,169,000 | $67,358,000 | $0 |
| Common Stock Issuance | $39,801,000 | $151,169,000 | $67,358,000 | $0 |
| Net Other Financing Charges | - | - | - | $-160,000 |
| Other | ||||
| Repayment Of Debt | $-1,855,000 | $0 | - | - |
| Issuance Of Debt | $0 | $24,488,000 | $0 | $95,783,000 |
| End Cash Position | $112,095,000 | $173,063,000 | $95,823,000 | $56,221,000 |
| Beginning Cash Position | $173,063,000 | $95,823,000 | $56,221,000 | $45,586,000 |
| Changes In Cash | $-60,968,000 | $77,240,000 | $39,602,000 | $10,635,000 |
| Proceeds From Stock Option Exercised | $1,972,000 | $18,962,000 | $49,573,000 | $1,511,000 |
| Net Issuance Payments Of Debt | $-1,855,000 | $24,488,000 | $0 | $95,783,000 |
| Net Long Term Debt Issuance | $-1,855,000 | $24,488,000 | $0 | $95,783,000 |
| Long Term Debt Payments | $-1,855,000 | $0 | - | - |
| Long Term Debt Issuance | $0 | $24,488,000 | $0 | $95,783,000 |
| Net Investment Purchase And Sale | $61,847,000 | $-20,318,000 | $-759,000 | $1,314,000 |
| Sale Of Investment | $139,247,000 | $107,705,000 | $49,073,000 | $64,323,000 |
| Purchase Of Investment | $-77,400,000 | $-128,023,000 | $-49,832,000 | $-63,009,000 |
| Net PPE Purchase And Sale | $-289,000 | $-295,000 | $-194,000 | $-254,000 |
| Purchase Of PPE | $-289,000 | $-295,000 | $-194,000 | $-254,000 |
| Change In Working Capital | $-27,914,000 | $4,933,000 | $3,336,000 | $-6,306,000 |
| Change In Other Working Capital | $-1,000 | $49,000 | - | - |
| Change In Other Current Liabilities | $-729,000 | $-237,000 | $-811,000 | $-1,652,000 |
| Change In Other Current Assets | $-4,572,000 | $1,449,000 | $702,000 | $-1,269,000 |
| Change In Payables And Accrued Expense | $3,232,000 | $10,649,000 | $6,712,000 | $1,590,000 |
| Change In Accrued Expense | $2,946,000 | $-244,000 | $2,557,000 | $1,309,000 |
| Change In Payable | $286,000 | $10,893,000 | $4,155,000 | $281,000 |
| Change In Account Payable | $286,000 | $10,893,000 | $4,155,000 | $281,000 |
| Change In Prepaid Assets | $-5,827,000 | $1,436,000 | $820,000 | $-3,626,000 |
| Change In Inventory | $-7,237,000 | $-3,554,000 | $-1,348,000 | $-362,000 |
| Change In Receivables | $-12,780,000 | $-4,859,000 | $-2,739,000 | $-987,000 |
| Changes In Account Receivables | $-12,780,000 | $-4,859,000 | $-2,739,000 | $-987,000 |
| Other Non Cash Items | $3,604,000 | $-1,305,000 | $1,014,000 | $2,624,000 |
| Stock Based Compensation | $11,959,000 | $13,108,000 | $9,343,000 | $10,580,000 |
| Amortization Of Securities | $-1,875,000 | $-2,891,000 | $-1,034,000 | $-498,000 |
| Depreciation Amortization Depletion | $2,411,000 | $1,186,000 | $1,705,000 | $1,817,000 |
| Depreciation And Amortization | $2,411,000 | $1,186,000 | $1,705,000 | $1,817,000 |
| Depreciation | $2,411,000 | $1,186,000 | $1,705,000 | $1,817,000 |
| Gain Loss On Investment Securities | $2,865,000 | $15,077,000 | $11,504,000 | $14,007,000 |
| Net Income From Continuing Operations | $-153,494,000 | $-126,874,000 | $-102,244,000 | $-109,783,000 |
Fetched: 2026-06-13